Author:
Wenderfer Scott,Mason Sherene,Bernal Christine,da Silva Clovis Artur Almeida
Publisher
Springer Berlin Heidelberg
Reference175 articles.
1. Access Trial Group T. Treatment of lupus nephritis with abatacept: the abatacept and cyclophosphamide combination efficacy and safety study. Arthritis Rheumatol. 2014;66(11):3096–104. https://doi.org/10.1002/art.38790.
2. Aikawa NE, Sallum AM, Pereira RM, Suzuki L, Viana VS, Bonfa E, et al. Subclinical impairment of ovarian reserve in juvenile systemic lupus erythematosus after cyclophosphamide therapy. Clin Exp Rheumatol. 2012;30(3):445–9. https://www.clinexprheumatol.org/abstract.asp?a=5323. PMID: 22703605 [PubMed].
3. Alshaiki F, Obaid E, Almuallim A, Taha R, El-Haddad H, Almoallim H. Outcomes of rituximab therapy in refractory lupus: a meta-analysis. Eur J Rheumatol. 2018;5(2):118–26. https://doi.org/10.5152/eurjrheum.2018.17096.
4. Anders H-J, Saxena R, Zhao M-H, Parodis I, Salmon JE, Mohan C. Lupus nephritis. Nat Rev Dis Primers. 2020;6(1):7. https://doi.org/10.1038/s41572-019-0141-9.
5. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20(5):1103–12. https://doi.org/10.1681/ASN.2008101028.